Worldwide, NDDs are supposed to double in the next 10-20 years and efficient solutions are even more needed in order to keep our NHS able to avoid dramatic situations in patient care and also state finance. 

As our molecule demonstrated both efficacy combined with an exceptional safety profile, we can target the treatment market, but also the prevention market which becomes more and more important. Indeed, all governments and health insurance system are looking for prevention, as this approach is less expensive, and a growing number of biomarkers (genetic and others) for early detection of risk of diseases are validated over the last years and become more and more common. However, prevention and long-term treatments need an exceptional safety profile without any toxicity and SIT161 fits to this necessity.  

As we know exactly the dosage for pre CTA work and also Ph. 1 clinical trial, we can perform those steps in a quick and cost-effective way. Ph. 2 clinical studies for final POC for NDDs in humans can be achieved with an exceptionally low cost and a major valorization of the company. 

*Please note that investments are subject to normal due diligence.